CGK- Partnering

CGK provides programs based on InCell IT technology to pharmaceutical companies and drug development companies.

Indication discovery program can help the companies with candidates that failed clinical trials due to reasons other than toxicity.

Target ID program can help companies developing a candidate with unknown target to determine the target to maximize the pipeline’s value.

Finding a new target or a new indication will benefit the drug development at any stage of its development.

Determination of off-target activities: at an early stage, InCell IT will reveal off target activities to predict unwanted adverse effect.
Finding a novel target: if the compound is proven to be potent for certain disease in animal test, the novel target determined by InCell IT can lead to a validation of novel target.
Finding a new indication: the compound may end up having more than one indication for maximize the market size.
Finding a new use for a failed drug: if the compound has failed its clnical trials due to lack of efficacy, it can be revived as a treatment of another disease.

CGK provides customized program based on the partner’s needs. For more information please contact;